Baloxavir-marboxil
General
Type : Pro-Drug || Drug || Not A\/B H target || Sulfur compound
Chemical_Nomenclature : [(3R)-2-[(11S)-7,8-difluoro-6,11-dihydrobenzo[c][1]benzothiepin-11-yl]-9,12-dioxo-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-dien-11-yl]oxymethyl methyl carbonate
Canonical SMILES : COC(=O)OCOC1=C2C(=O)N3CCOCC3N(N2C=CC1=O)C4C5=C(CSC6=CC=CC=C46)C(=C(C=C5)F)F
InChI : InChI=1S\/C27H23F2N3O7S\/c1-36-27(35)39-14-38-25-19(33)8-9-31-24(25)26(34)30-10-11-37-12-21(30)32(31)23-15-6-7-18(28)22(29)17(15)13-40-20-5-3-2-4-16(20)23\/h2-9,21,23H,10-14H2,1H3\/t21-,23+\/m1\/s1
InChIKey : RZVPBGBYGMDSBG-GGAORHGYSA-N
Other name(s) : Baloxavir marboxil, Xofluza, S-033188, CHEMBL4297503, SCHEMBL20108731, DB13997
Target
Families : Arylacetamide_deacetylase
References (1)
| Title : Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza - Koshimichi_2019_J.Pharm.Sci_108_1896 |
| Author(s) : Koshimichi H , Tsuda Y , Ishibashi T , Wajima T |
| Ref : J Pharm Sci , 108 :1896 , 2019 |
| Abstract : Koshimichi_2019_J.Pharm.Sci_108_1896 |
| ESTHER : Koshimichi_2019_J.Pharm.Sci_108_1896 |
| PubMedSearch : Koshimichi_2019_J.Pharm.Sci_108_1896 |
| PubMedID: 30557562 |